Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atlantic Therapeutics Appoints Former Zeltiq CEO As Chairman

Executive Summary

Atlantic Therapeutics has appointed former Zeltiq Aesthetics CEO Gordie Nye as its new chairman to help drive adoption of its CE-marked Innovo device for treating clinical conditions associated with pelvic floor weakness.

You may also be interested in...



Start-Up Spotlight: Atlantic Therapeutics, Stimulating The Stress Incontinence Market With Vaginal Mesh Alternative

While controversy over vaginal mesh implants and the serious complications resulting from these devices eroding inside the patient continue unabated across the globe, one Irish company is looking to capitalize on this opportune time by offering a noninvasive solution to stress urinary incontinence. Atlantic Therapeutics has recently won the backing of European healthcare VCs, raising €15m in a Series A round. 

Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business

Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.

Lilly Gets First Of Its Kind FDA Citation For Trulicity Instagram Post

Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.

Topics

UsernamePublicRestriction

Register

MT105217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel